Bristol Myers Squibb to present new clinical and HEOR data on Cobenfy in schizophrenia at Psych Congress 2024
Bristol Myers Squibb announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating obenfy (xanomeline and trospium chloride) in schizophrenia in… read more.
